Lenalidomide - Generic Drug Details

What are the generic drug sources for lenalidomide and what is the scope of freedom to operate?

Lenalidomide is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Alvogen, Amneal, Apotex, Arrow Intl, Biocon Pharma, Cipla, Deva Holding As, Dr Reddys, Eugia Pharma, Hetero Labs Ltd V, Lupin, Mylan, Novugen, Qilu, Sun Pharm, Torrent, Zydus Pharms, and Bristol Myers Squibb, and is included in twenty-one NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lenalidomide has three hundred and thirty-one patent family members in forty-one countries.

There are fourteen drug master file entries for lenalidomide. Nineteen suppliers are listed for this compound.

Summary for lenalidomide

International Patents:	331
US Patents:	2
Tradenames:	2
Applicants:	19
NDAs:	21
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	19
Raw Ingredient (Bulk) Api Vendors:	122
Clinical Trials:	1,236
Patent Applications:	5,828
Drug Prices:	Drug price trends for lenalidomide
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lenalidomide
What excipients (inactive ingredients) are in lenalidomide?	lenalidomide excipients list
DailyMed Link:	lenalidomide at DailyMed

See drug prices for lenalidomide

Recent Clinical Trials for lenalidomide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Andrew Hantel, MD	PHASE1
PrECOG, LLC.	PHASE3
Massachusetts General Hospital	PHASE2

See all lenalidomide clinical trials

Pharmacology for lenalidomide

Drug Class

Thalidomide Analog

Anatomical Therapeutic Chemical (ATC) Classes for lenalidomide

L04AX	Other immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for LENALIDOMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
REVLIMID	Capsules	lenalidomide	2.5 mg and 20 mg	021880	1	2016-07-12
REVLIMID	Capsules	lenalidomide	5 mg, 10 mg and 15 mg	021880	1	2010-08-30
REVLIMID	Capsules	lenalidomide	25 mg	021880	1	2010-07-12

US Patents and Regulatory Information for lenalidomide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	LENALIDOMIDE	lenalidomide	CAPSULE;ORAL	218872-005	Nov 14, 2025	AB	RX	No	No
Eugia Pharma	LENALIDOMIDE	lenalidomide	CAPSULE;ORAL	213885-003	Mar 6, 2023	AB	RX	No	No
Deva Holding As	LENALIDOMIDE	lenalidomide	CAPSULE;ORAL	217554-005	May 22, 2025	AB	RX	No	No
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	AB	RX	Yes	No	7,465,800		Y	Y
Arrow Intl	LENALIDOMIDE	lenalidomide	CAPSULE;ORAL	201452-003	May 21, 2021	AB	RX	No	No
Dr Reddys	LENALIDOMIDE	lenalidomide	CAPSULE;ORAL	209348-001	Oct 14, 2021	AB	RX	No	No

Expired US Patents for lenalidomide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	9,101,622
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006	6,561,976
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	6,561,976
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006	8,492,406
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-001	Dec 27, 2005	8,204,763
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-001	Dec 27, 2005	9,155,730

EU/EMA Drug Approvals for lenalidomide

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Ireland Limited	Lenalidomide Mylan	lenalidomide	EMEA/H/C/005306Multiple myelomaLenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).	Authorised	yes	no	no	2020-12-18
Accord Healthcare S.L.U.	Lenalidomide Accord	lenalidomide	EMEA/H/C/004857Multiple myelomaLenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Accord in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).	Authorised	yes	no	no	2018-09-20
Bristol-Myers Squibb Pharma EEIG	Revlimid	lenalidomide	EMEA/H/C/000717Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).	Authorised	no	no	no	2007-06-14
Krka, d.d., Novo mesto	Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)	lenalidomide	EMEA/H/C/005348Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1).Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1).Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).	Authorised	yes	no	no	2021-02-11
Krka, d.d., Novo mesto	Lenalidomide Krka d.d.	lenalidomide	EMEA/H/C/005729Multiple myelomaLenalidomide Krka d.d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Krka d.d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Krka d.d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesLenalidomide Krka d.d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Follicular lymphomaLenalidomide Krka d.d. in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).	Withdrawn	yes	no	no	2021-02-11
Krka, d.d., Novo mesto	Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)	lenalidomide	EMEA/H/C/005734Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).	Authorised	yes	no	no	2021-02-11

International Patents for lenalidomide

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	2324	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
Argentina	047994	FORMAS POLIMORFICAS DE 3-(4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PIPERIDIN-2,6-DIONA
Argentina	057868	METODOS EN LOS QUE SE USA 3-(4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PIPERIDIN-2,6-DIONA PARA EL TRATAMIENTO DE CIERTAS LEUCEMIAS
Argentina	102756	FORMAS POLIMÓRFICAS DE 3-(4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PIPERIDIN-2,6-DIONA Y COMPOSICIONES QUE LAS COMPRENDEN
Austria	459357
Austria	531369

Supplementary Protection Certificates for lenalidomide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2105135	CA 2015 00006	Denmark		PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805
2105135	C20150005 00140	Estonia		PRODUCT NAME: POMALIDOMIID;REG NO/DATE: EU/1/13/850 08.08.2013
2105135	00140	Estonia
0925294	SPC/GB07/047	United Kingdom		PRODUCT NAME: LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/07/391/001 20070619; UK EU/1/07/391/002 20070619; UK EU/1/07/391/003 20070619; UK EU/1/07/391/004 20070619
2105135	1590004-6	Sweden		PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808
2105135	300717	Netherlands		PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805

Last updated: August 10, 2026

Lenalidomide is a mature, high-value multiple myeloma medicine entering the steepest phase of patent-driven revenue erosion. Bristol Myers Squibb’s Revlimid revenue fell from approximately $12.8 billion in 2021 to about $5.8 billion in 2024 as U.S. authorized generics and international generic competition expanded. The asset remains commercially important because of long treatment duration and broad use in multiple myeloma, but its financial profile is shifting from growth product to declining cash generator. [1][2]

Lenalidomide Market Dynamics, Patent Expiration, Generic Competition, and Financial Trajectory

What is lenalidomide and how is it used?

Lenalidomide is an oral immunomodulatory drug derived from thalidomide. It is marketed primarily as Revlimid by Bristol Myers Squibb following its acquisition of Celgene in 2019.

The drug is approved in the United States for:

• Multiple myeloma, in combination with dexamethasone and in maintenance therapy after autologous hematopoietic stem-cell transplantation.
• Transfusion-dependent anemia associated with low- or intermediate-1-risk myelodysplastic syndromes with a deletion 5q abnormality.
• Mantle cell lymphoma after at least two prior therapies, including bortezomib, although the commercial relevance of this indication is substantially lower than multiple myeloma. [3]

Lenalidomide’s market position rests on three factors:

1. Long treatment duration, particularly in multiple myeloma maintenance.
2. Established clinical guidelines and physician familiarity.
3. A large installed patient base despite the arrival of newer multiple myeloma therapies.

Its main commercial weakness is that it is a small-molecule product with generic substitution potential. Unlike biologic oncology products, it does not face a biosimilar pathway. Generic manufacturers can seek abbreviated new drug approval under the ANDA process.

How large is the lenalidomide market?

Revlimid generated approximately $5.8 billion in worldwide revenue for Bristol Myers Squibb in 2024. That represented roughly 12% of BMS’s total revenue of approximately $48.3 billion. Revlimid revenue was approximately $6.1 billion in 2023 and $6.4 billion in 2022. [1][2]

Revlimid revenue trajectory

Year	Approximate Revlimid revenue	Year-over-year direction	Primary market factor
2019	$9.9 billion	Growth	Continued multiple myeloma expansion
2020	$12.1 billion	Growth	Expanded treatment and maintenance use
2021	$12.8 billion	Growth	Peak commercial period
2022	$6.4 billion	Sharp decline	U.S. authorized generic entry
2023	$6.1 billion	Decline	Broader generic penetration
2024	$5.8 billion	Decline	Continued generic substitution and market maturity

Figures are rounded from Bristol Myers Squibb annual filings and product disclosures. [1][2]

The apparent decline began abruptly rather than gradually. Revlimid was one of Celgene’s principal growth engines before generic entry. After limited U.S. generic launches began, revenue fell by roughly half between 2021 and 2022.

When did lenalidomide lose exclusivity?

Lenalidomide lost effective commercial exclusivity in stages rather than on one universal date.

U.S. exclusivity timeline

Event	Approximate timing	Commercial effect
Core U.S. composition patent granted	1997	Established primary patent protection
Core patent term	2027, subject to applicable patent-term calculations	Delayed unrestricted generic competition
U.S. generic settlements	2010s onward	Created controlled market-entry rights
First limited U.S. generic launches	March 2022	Began material Revlimid erosion
Expanded annual generic access	2023-2025	Increased substitution and price pressure
Broad generic competition	Expected around 2026-2027, subject to patent and settlement terms	Creates the largest remaining erosion event

The key U.S. patent is U.S. Patent No. 5,635,517, which covers lenalidomide and has been associated with protection extending into 2027 after patent-term adjustments and related regulatory considerations. The practical launch dates for individual generic companies are controlled by settlement agreements, patent challenges, and FDA approval status rather than by the composition patent alone. [4][5]

The U.S. market therefore had partial generic competition well before the end of the core patent term. This is a common pattern for high-value oncology products: settlements convert a binary patent dispute into staged generic access.

What patents protect Revlimid and lenalidomide?

The lenalidomide patent estate includes several protection layers:

• Composition-of-matter protection for lenalidomide.
• Patents covering chemical intermediates and manufacturing processes.
• Formulation and dosage-form claims.
• Treatment methods for multiple myeloma and other hematologic cancers.
• Patents covering risk-management and controlled-distribution systems.
• Patents directed to particular patient populations or dosing schedules.

Core patent protection

U.S. Patent No. 5,635,517 is the principal composition patent historically associated with Revlimid. Its broad commercial value came from covering the active pharmaceutical ingredient rather than only a formulation or narrow indication. [4]

The remaining estate is less economically durable than the core composition patent. Formulation, process, and method-of-use patents may create litigation leverage, but they generally do not prevent all generic entry once ANDAs are approved and settlement rights become effective.

Formulation patents

Formulation protection is relevant to lenalidomide because Revlimid is supplied in multiple oral capsule strengths, commonly 2.5 mg, 5 mg, 10 mg, 15 mg, and 25 mg in the United States.

Formulation and capsule patents can affect:

• The timing of specific strengths.
• The ability of a generic to copy the reference product.
• Manufacturing cost and yield.
• Product labeling and risk-management compliance.
• The scope of a Paragraph IV certification.

Formulation patents are less likely to preserve the full branded price after an approved generic has entered. Their main commercial role is to delay, segment, or complicate competition.

What is the Orange Book status of Revlimid?

Revlimid is an FDA-approved small-molecule drug listed in the Orange Book. The Orange Book identifies approved products, patent information submitted by the sponsor, and applicable exclusivity data. [5]

The listed patent estate has been central to multiple Paragraph IV disputes. Generic applicants challenging listed patents may certify that the patents are invalid, unenforceable, or will not be infringed. The filing of a Paragraph IV certification can trigger patent litigation and an automatic FDA approval stay of up to 30 months under the Hatch-Waxman framework, subject to statutory exceptions. [6]

The commercial consequences depend on:

• Whether the generic applicant has a first-to-file position.
• Whether the patent holder sues within the statutory period.
• Whether the parties settle.
• Whether the settlement permits an authorized or independent generic launch.
• Whether FDA approval is granted before the negotiated entry date.

Which companies have challenged lenalidomide patents?

Generic and specialty pharmaceutical companies have challenged or negotiated access to Revlimid, including firms such as Natco Pharma, Teva Pharmaceuticals, Dr. Reddy’s Laboratories, Cipla, Zydus, Sun Pharmaceutical Industries, and other ANDA applicants.

Natco was particularly important because of its relationship with Teva in the U.S. generic market. The settlement structure allowed limited entry before the end of the core patent term. Other companies obtained their own settlement rights or entered after patent and regulatory developments.

The competitive field has two distinct groups:

U.S. limited-entry suppliers

These suppliers operate under negotiated volume or timing restrictions. They can capture revenue while limiting the speed of substitution against Revlimid.

Post-settlement generic suppliers

These companies are positioned to compete more aggressively when broader entry becomes available. Their economic model depends on low-cost production, FDA approval across all commercially relevant strengths, and access to the restricted distribution system.

What Paragraph IV challenges affected Revlimid?

Paragraph IV challenges targeted the patents listed for Revlimid in the FDA Orange Book. The disputes involved the active ingredient, formulations, methods of treatment, and related patent claims.

The most important commercial outcome was settlement rather than a final invalidity judgment. Settlements preserved some patent value for BMS while granting generic companies defined launch rights.

A staged settlement can be financially attractive to both sides:

• The originator preserves a period of high-margin revenue.
• The generic receives a legally defined launch date.
• Litigation costs and invalidity risk are reduced.
• Investors receive greater visibility into the erosion curve.

The drawback for the originator is that early authorized generic access can reduce branded revenue before complete patent expiry. The drawback for the generic entrant is that market share and supply may be restricted until the final settlement date.

How strong is the lenalidomide patent estate?

The estate is commercially strong but no longer capable of preserving full exclusivity.

Strengths

• A historically significant composition patent.
• Multiple patent layers across formulations and methods of use.
• High clinical dependence in maintenance therapy.
• Complex oncology distribution and safety requirements.
• Significant litigation value because Revlimid generated billions of dollars annually.

Weaknesses

• The active ingredient is a small molecule with a clear generic pathway.
• Authorized generics have already established substitution.
• The principal revenue source is concentrated in multiple myeloma, where alternative agents are available.
• Method-of-use patents are difficult to enforce against widespread prescribing.
• Formulation patents generally support delay rather than permanent market protection.
• Settlement-based entry has reduced the value of remaining exclusivity.

The estate should therefore be classified as strong for delaying erosion, but weak for preventing long-term generic commoditization.

What generic entry risks exist for lenalidomide?

The main risk is a transition from controlled competition to broad multi-source generic competition around the end of the remaining U.S. settlement and patent period.

Generic launch scenarios

Scenario	Timing	Expected commercial result
Controlled entry	2022-2025	Gradual volume migration with partial price protection
Broad U.S. entry	Around 2026-2027	Accelerated substitution and steep price decline
Multi-source competition	After unrestricted entry	Lower prices, lower branded share, reduced generic margins
Delayed entry from litigation	Case-specific	Temporary protection for affected strengths or applicants

Lenalidomide has an unusual risk-management burden. In the United States, the product is distributed through a restricted program because of teratogenicity concerns. Generic manufacturers must meet applicable risk-evaluation and mitigation requirements, which can slow operational launch and limit the number of immediately capable competitors. [3]

That barrier is meaningful but temporary. It increases execution complexity without creating durable exclusivity.

Does lenalidomide face biosimilar competition?

No. Lenalidomide is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is generic ANDA approval, not biosimilar approval under the Public Health Service Act.

The market risks are therefore:

• Abbreviated approval.
• Paragraph IV patent litigation.
• Authorized generic competition.
• Therapeutic substitution.
• Price compression.

Biosimilar developers are not the relevant competitive set for Revlimid.

How is the competitive landscape changing?

Lenalidomide remains a major backbone therapy in multiple myeloma, but its strategic position is being reduced by newer therapies.

Relevant competing or complementary products include:

• Pomalidomide, another immunomodulatory agent marketed by BMS as Pomalyst.
• Bortezomib and other proteasome inhibitors.
• Daratumumab and other anti-CD38 antibodies.
• Carfilzomib and ixazomib.
• Selinexor.
• Chimeric antigen receptor T-cell therapies.
• Bispecific antibodies targeting BCMA or other plasma-cell antigens.

Lenalidomide is most exposed in relapsed or refractory disease, where treatment sequencing is changing quickly. Maintenance therapy remains more defensible because of established evidence and clinical practice patterns.

The main competitive pressure is not immediate replacement across every patient. It is reduced new-patient initiation, earlier switching, lower treatment duration in some lines, and lower net pricing after generic substitution.

What is the financial trajectory for Bristol Myers Squibb?

Revlimid is moving from a growth asset to a declining but still material cash-flow contributor.

Revenue exposure

At approximately $5.8 billion in 2024 revenue, Revlimid accounted for about one-eighth of BMS’s total sales. That exposure is smaller than BMS’s Eliquis and Opdivo franchises, but it remains large enough to affect earnings expectations and portfolio planning. [1]

The financial trajectory has four phases:

1. Peak growth through 2021.
2. Initial generic shock in 2022.
3. Managed erosion through 2024 and 2025.
4. Steeper decline after broad U.S. generic access.

A reasonable directional model is:

Period	Revenue outlook	Main driver
2024	Approximately $5.8 billion	Continued controlled generic erosion
2025	Lower than 2024	More generic volume and price pressure
2026	Potentially sharply lower	Broader U.S. entry
2027 onward	Mature residual brand revenue	Maintenance demand, loyalty, and geographic variation

The residual branded business will likely persist because some physicians and patients remain on the reference product, some markets have slower substitution, and certain reimbursement systems do not immediately force switching. The residual revenue will not preserve the historical profit pool.

What licensing deals affect lenalidomide?

The most consequential commercial arrangements were the Celgene settlements with generic applicants, including agreements that later affected Teva and Natco’s U.S. commercialization rights.

These arrangements functioned as patent settlements rather than ordinary licensing transactions. They granted defined entry rights and commercial access in exchange for resolving litigation risk.

Celgene also used regional partnerships and distribution arrangements for Revlimid in some markets. After BMS acquired Celgene, the economic benefits and obligations associated with these arrangements became part of BMS’s oncology portfolio.

The licensing value of lenalidomide is now lower than during its growth phase. New agreements are more likely to concern:

• Regional generic rights.
• Authorized generic supply.
• Manufacturing and distribution.
• Combination-product development.
• Lifecycle management in selected jurisdictions.

What is the regulatory status of lenalidomide?

Revlimid has full FDA approval for its principal hematologic indications. Its U.S. distribution is subject to a restricted program because of serious embryo-fetal toxicity risks.

The regulatory environment affects competition in two ways:

• Generic applicants must satisfy ANDA requirements and demonstrate therapeutic equivalence.
• Manufacturers must comply with the applicable restricted-distribution and risk-management framework.

This regulatory burden raises launch costs and operational complexity. It does not eliminate generic competition. Once a generic has approval, the safety program can become a competitive filter that favors manufacturers with established oncology infrastructure.

What manufacturing and IP barriers protect lenalidomide?

Manufacturing barriers are moderate. Lenalidomide is not a biologic and does not require cell culture, viral clearance, or cold-chain manufacturing. The principal barriers are:

• Active pharmaceutical ingredient quality and supply.
• Control of impurities and process consistency.
• Capsule manufacturing across multiple strengths.
• Regulatory compliance for a teratogenic oncology drug.
• Enrollment and operation within restricted distribution systems.
• Inventory management for a high-cost product with declining prices.

The strongest barrier is regulatory execution rather than manufacturing science. Over time, multiple suppliers can overcome that barrier, particularly in markets with established generic oncology networks.

How does lenalidomide compare with pomalidomide?

Attribute	Lenalidomide	Pomalidomide
Brand	Revlimid	Pomalyst
Company	Bristol Myers Squibb	Bristol Myers Squibb
Main use	Multiple myeloma, especially earlier lines and maintenance	Relapsed or refractory multiple myeloma
Commercial maturity	Earlier and larger franchise	Smaller, later-stage franchise
Generic risk	Active and material	Later-stage risk profile
Revenue exposure	Multi-billion-dollar historical franchise	Smaller but strategically relevant
Strategic role	Backbone therapy with major generic erosion	Later-line immunomodulatory option

Lenalidomide has the larger installed base and greater revenue exposure. Pomalidomide may retain more commercial protection for a longer period, but it operates in a narrower and more heavily pretreated patient population.

What litigation and settlement risks remain?

The principal legal risk is not whether generic competition will arrive. It is the timing, scope, and speed of unrestricted entry.

Key variables include:

• Patent validity and enforceability.
• Settlement dates for individual applicants.
• ANDA approval timing.
• First-filer rights.
• Distribution-program compliance.
• Potential litigation over later-issued patents.
• Product-specific differences across strengths and indications.

The originator may pursue additional patents covering formulations, dosing, or manufacturing. Such patents can create litigation and delay for individual products, but they are unlikely to restore the historical level of exclusivity once several generic suppliers are active.

Key Takeaways

• Revlimid remains one of the largest declining pharmaceutical franchises in the industry.
• BMS revenue fell from approximately $12.8 billion in 2021 to $5.8 billion in 2024.
• U.S. generic entry began on a limited basis in 2022 under patent settlements.
• Broader generic competition around 2026-2027 is the main remaining erosion event.
• Lenalidomide faces generic, not biosimilar, competition.
• The patent estate is effective at delaying entry but cannot prevent long-term price compression.
• Maintenance multiple myeloma therapy is the most durable part of the commercial franchise.
• Newer multiple myeloma therapies are reducing dependence on lenalidomide in later-line treatment.
• BMS’s remaining exposure is still large, with Revlimid representing roughly 12% of 2024 company revenue.
• Manufacturing barriers are moderate; restricted distribution and regulatory compliance are the more important entry hurdles.

FAQs About Lenalidomide Market and Patent Risk

When will generic lenalidomide become widely available in the United States?

Broad U.S. generic competition is expected around the 2026-2027 period, although individual companies may have different settlement-based entry dates and FDA approval timing.

Is Revlimid still protected by patents?

Yes. Revlimid retains a layered patent estate, including the core U.S. composition patent and later formulation, method-of-use, and process patents. Limited generic entry has already occurred under settlement arrangements.

Why did Revlimid sales fall so sharply after 2021?

The main cause was controlled U.S. generic entry beginning in 2022. Generic substitution reduced both branded volume and net pricing.

Can a generic manufacturer launch lenalidomide without joining a restricted distribution program?

A manufacturer must comply with applicable FDA safety and distribution requirements. Failure to establish compliant controls can prevent commercial launch even after ANDA approval.

Will lenalidomide remain important after generic competition expands?

Yes, clinically. It is likely to remain widely used in multiple myeloma, particularly maintenance therapy. The commercial value will shift from branded revenue to lower-priced generic volume.

References

1. Bristol Myers Squibb. (2025). 2024 annual report. Bristol Myers Squibb Company.

2. Bristol Myers Squibb. (2024). 2023 annual report. Bristol Myers Squibb Company.

3. U.S. Food and Drug Administration. (2024). Revlimid (lenalidomide) prescribing information. FDA.

4. U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,635,517: Substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-diones. U.S. Department of Commerce.

5. U.S. Food and Drug Administration. (2025). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

6. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.